Navigation Links
According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
Date:11/5/2008

SAN MATEO, Calif., Nov. 5 /PRNewswire/ -- In a survey of 100 infectious disease specialists following last week's ICAAC/IDSA Annual Meeting, Merck was perceived as standing out above other companies at the conference, while Tibotec Therapeutics was perceived as having the best overall image in infectious disease. GlaxoSmithKline, Pfizer and Cubist Pharmaceuticals rounded out the top companies in overall image among the specialists.

The 2008 ICAAC/IDSA Annual meeting -- one of the largest meetings attended by infectious disease specialists -- was held from October 25-28 in Washington D.C. AlphaDetail conducted a brief AlphaPulse(TM) survey of 100 infectious disease specialists to gauge physician reaction to data presented at the meeting. Of the respondents, half attended the 2008 meeting.

When asked their opinion about what the most important data presented at this year's conference was, nearly half of the respondents cited topics focused on HIV, particularly findings in initiating earlier treatment, the approval of a new dosing regimen for Prezista in naive patients, and data about newer HIV treatments showing promise as 1st line therapies. New MRSA data was also cited frequently.

"There was new data presented on HIV treatment regarding use of either

Prezista or raltegravir as first-line agents".

-- Infectious Disease Specialist, 11/08

When prompted with data presented at the conference, the majority of respondents revealed that the most important study indicated a 70% improvement in survival for patients who initiated HAART therapy with CD4 counts between 351 and 500 vs. those who initiated at 350 and below. Interestingly, a large percentage of respondents also highlighted key findings about a compound (TMC207) as important news that they were not familiar with prior to the meeting.

To receive the full AlphaPulse(TM) report at no charge, please contact Bob Latshaw at (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our client's most challenging questions.

Footnotes:

The 48th Annual Interscience Conference on Antimicrobial Agents and

Chemotherapy (ICAAC) and 46th Annual Infectious Disease Society of America

(IDSA) meeting was held from October 25-28 in Washington DC.


'/>"/>
SOURCE AlphaDetail, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Global Agricultural and Environmental Diagnostics Market to Reach $2.4 Billion by 2012, According to New Report by Global Industry Analysts
2. World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
3. World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc.
4. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
5. Biomoda, Inc. (BMOD) SqueezeTrigger Price is $0.27. Approximately 1 Million Shares Shorted Since November 2006 According to Buyins.net Research Report
6. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
7. Genetic Testing Market to Exceed $6.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
8. Titrators Market to Reach $315 Million by 2015, According to New Report by Global Industry Analysts, Inc.
9. Laboratory Pumping Systems to Reach $3.1 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
10. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
11. New Bill to Expand Promotion of Biofuels Is a Welcome Boost for U.S.-Brazil Relations According to Brazilian Sugarcane Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 /PRNewswire/ - FACIT announced a seed stage ... a start-up created by FACIT focused on developing ... combined with non-dilutive capital, achieves a targeted $3.0M ... enables Propellon to accelerate the nomination of a ... and/or entering a strategic partnership for clinical trials ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... acquire information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or ... N-glycosylation profiling of therapeutic antibodies. , To meet this demand, the team ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Functional near-infrared spectroscopy ... is being explored as a way to track the brain’s response to acute pain ... activation by cold pressor test ,” published today in the journal Neurophotonics , ...
(Date:3/22/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced Alexey Eliseev ... at the 5th Annual Cancer BioPartnering & Investment ... present to and meet with thought leaders from ... as well as institutional investors. This event will ...
Breaking Biology Technology:
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):